Alkylating agent Evidence:
Treatment of metastatic malignant melanoma and 2nd-line therapy for Hodgkin's disease in combination with other agents.
Adults: Malignant Melanoma: 2-4.5mg/kg/day for 10 days. May repeat every 4 weeks. Alternate 22
Dosage: 250mg/m /day IV for 5 days. May repeat every 3 weeks. Hodgkin's Disease: 150mg/m
/day for 5 days. May repeat every 4 weeks. Alternate Dosage: 375mg/m on Day 1, to be repeated every 15 days.
Inj: 200mg Evidence:
Hemopoietic depression, hepatic necrosis, anorexia, N/V.
Pregnancy class safety
Category C, not for use in nursing.
Metabolism: Extensive; 5-aminoimidazole-4-carboxamide (major metabolite). Elimination:
Urine (40% unchanged), T=5 hrs.
Monitor for signs/symptoms of hemopoietic depression/toxicity, hepatic necrosis/toxicity, anaphylaxis, and inj-site reaction. Monitor WBC, RBC, and platelet levels for possible bone marrow depression.
Administration: IV route. Storage: 2-8°C (36-46°F). Reconstituted Sol: 4°C for up to 72 hrs or at normal room conditions (temperature and light) for up to 8 hrs. Reconstituted Sol (diluted further):